Childhood cancers trials in Spain

In Spain 152 Also abroad 2459

152 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
Where
Barakaldo, Barcelona, Madrid, Murcia, Santa Cruz de Tenerife, Seville, Valencia, Zaragoza
Age
4 years and over
People
530 worldwide
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07871864
Phase 3Taking people
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
Where
Barcelona, Madrid, Valencia
Age
6 months and over
People
433 worldwide
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT05476939 · EU 2023-506027-29-00
Phase 3Taking people
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Where
Alcalá de Henares, Alicante, Badalona, Barcelona, Burgos, Cáceres, Granada, Las Palmas De Gran Canaria, L'Hospitalet de Llobregat, Madrid, Málaga, Oviedo, Palma, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Sevilla, Tarragona, Valencia
Age
12 years and over
People
468 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00
Phase 3Taking people
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Where
Badalona, Barcelona, Madrid, Santander, Seville, Valencia
People
115 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT03394365 · EU 2024-516622-57-00
Phase 3Taking people
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Where
Barcelona, Madrid, Sevilla, Valencia
Age
1 day to 1 year
People
160 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05327894 · EU 2022-502503-30-00
Phase 3Taking people
Teicoplanin as Infection Prophylaxis in Pediatric Acute Myeloid Leukemia (Pro-Teico study)
Where
Alicante, Barcelona, Esplugues De Llobregat, Madrid, Málaga, Palma, Santiago De Compostela, Valencia, Zaragoza
Age
Up to 64 years
People
128 worldwide
Run by
Prinses Maxima Centrum voor Kinderoncologie B.V.
See details and how to join2023-506546-23-00 · EU 2023-506546-23-00
Phase 1/2Taking people
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
Where
Badalona, Barcelona, Salamanca, Santander
Age
12 years and over
People
83 worldwide
Run by
AstraZeneca
See details and how to joinNCT07109219 · EU 2025-522372-93-00
Phase 2Taking people
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Where
Madrid
Age
Up to 19 years
People
232 worldwide
Run by
Medical University of Vienna
See details and how to joinNCT01356290 · EU 2024-515626-92-00
Phase 1/2Taking people
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Where
Barcelona, Madrid, Salamanca, Sevilla, Valencia
Age
12 years and over
People
255 worldwide
Run by
AstraZeneca
See details and how to joinNCT06137118 · EU 2023-505840-20-00
Phase 1/2Taking people
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Where
L'Hospitalet de Llobregat, Madrid
Age
12 years and over
People
161 worldwide
Run by
AstraZeneca
See details and how to joinNCT06137144 · EU 2023-506747-42-00
Phase 1Taking people
A study of Mirdametinib in Infants and Toddlers under 24months of age with Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PNs)
Where
Esplugues de Llobregat, Madrid
Age
Up to 17 years
People
8 worldwide
Run by
Merck Healthcare KGaA
See details and how to join2025-522000-24-00 · EU 2025-522000-24-00
Phase 1/2Taking people
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Where
Barcelona, Madrid, Valencia
Age
1 year to 17 years
People
70 worldwide
Run by
Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00
Phase 1/2Taking people
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Where
L'Hospitalet de Llobregat, Sevilla, Valencia
Age
30 days and over
People
447 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00
Phase 1Taking people
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Where
Barcelona, Madrid
Age
0 years to 18 years
People
30 worldwide
Run by
Autolus Limited
See details and how to joinNCT06173518 · EU 2023-506307-26-00
Phase 1Taking people
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Where
Barcelona, Madrid, Pamplona
Age
15 years and over
People
282 worldwide
Run by
Xencor, Inc.
See details and how to joinNCT06276491
Phase 1Taking people
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Where
Barcelona, Madrid
Age
0 years to 21 years
People
20 worldwide
Run by
PedAL BCU, LLC
See details and how to joinNCT06376162 · EU 2023-505262-28-00
Phase 1/2Not yet taking people in Spain
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL
Where
Barcelona, Esplugues de Llobregat, Madrid
Age
Up to 64 years
People
22 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-522019-40-00 · EU 2025-522019-40-00
Phase 2/3Taking people
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Where
Badalona, Barcelona, Cáceres, Girona, Jerez de la Frontera, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga, Murcia, Santander, Santiago de Compostela, Valencia
Age
18 years and over
People
740 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00
Phase 1/2Taking people
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Where
Barcelona, Esplugues de Llobregat, Madrid, Valencia
Age
1 month to 17 years
People
50 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06941272 · EU 2024-518771-66-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Barcelona, Madrid, Rioja, Valencia
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
No phaseTaking people
A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
Where
Barcelona
People
170 worldwide
Run by
Chiesi Farmaceutici S.p.A.
See details and how to joinNCT06423573
Phase 1/2Taking people
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Where
Barcelona, Esplugues De Llobregat, Madrid, Pamplona, Sevilla, Valencia
Age
Up to 25 years
People
75 worldwide
Run by
Turning Point Therapeutics, Inc.
See details and how to joinNCT04094610 · EU 2023-506464-14-00
Phase 1/2Taking people
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Where
A Coruña, Barcelona, Madrid
Age
12 years and over
People
359 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00
Phase 2Taking people
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Where
Barcelona, Esplugues de Llobregat, Madrid, Murcia, Santiago De Compostela, Sevilla, Valencia
Age
1 year to 17 years
People
100 worldwide
Run by
Pfizer
See details and how to joinNCT05748171 · EU 2023-509810-13-00
Phase 3Taking people
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)
Where
Alicante, Badajoz, Barakaldo, Barcelona, Esplugues De Llobregat, Las Palmas de Gran Canaria, Madrid, Málaga, Murcia, Oviedo, Palma, Santander, Santiago de Compostela, Sevilla, Valencia, Zaragoza
Age
Up to 64 years
People
675 worldwide
Run by
Prinses Maxima Centrum voor Kinderoncologie B.V.
See details and how to join2023-504999-25-00 · EU 2023-504999-25-00